Lipophilic thiamine (vitamin B1) derivative

Sulbutiamine

The French Arcalion product information gives sulbutiamine's half-life as about 5 hours, and the app lists 5 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Sulbutiamine after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.

Drawn from the half-life in the app's model, ~5 h. The model's figures

Sulbutiamine is a thiamine (vitamin B1) derivative, and Starling-Soares and colleagues write that its structural modifications "increase the lipophilic characteristic of this derivative compared to thiamine".2 The same review (Journal of Nutrition and Metabolism, 2020; authors at the Extreme Sports Nutrition Institute in Brazil, Lund University and the University of Liège) says it was "developed in Japan in the mid-60's as a beriberi treatment drug".2 It reports that a French pharmaceutical laboratory "launched sulbutiamine under the brand name Arcalion labeled as an anti-asthenia drug" in the 1970s, and that it is also sold as Enerion (Egis Pharmaceuticals).2 The review's authors declare no conflicts of interest and conclude that "methodological concerns need to be addressed and new studies are necessary, especially randomized controlled trials".2

The French product information for Arcalion 200 mg (Laboratoires Servier) lists one indication, "Traitement de certains états d'inhibition physique ou psychique avec baisse d'activité et apathie".1 It adds that in a confirmed depressive episode the medicine does not replace a specific antidepressant treatment.1 Van Reeth, of the Université Libre de Bruxelles, reviewed the animal and human literature in Drugs of Today in 1999, calling sulbutiamine "a highly lipophilic thiamine derivative".3 The app grades the evidence as emerging and describes use for mental fatigue and pre-workout focus. No controlled trial of sulbutiamine for focus or exercise performance in healthy adults was identified among the 20 PubMed records listed for "sulbutiamine" (44 matched) or in ClinicalTrials.gov, where the one registered study is in children with enuresis.

Sevim and colleagues (Mersin University, Multiple Sclerosis and Related Disorders, 2017) describe sulbutiamine as "a lipophilic compound that crosses the blood-brain barrier more readily than thiamine and increases the levels of thiamine and thiamine phosphate esters in the brain".4 The 2020 review states that in vivo experiments showed sulbutiamine "can be transformed into thiamine derivatives after the reduction of the disulfide bond and regeneration of the closed thiazolium rings".2 It also notes that the molecule "has never been identified in animal brain in its natural chemical structure after oral or even parenteral administration".2 The 1990 paper by Bettendorff and colleagues (University of Liège, Biochemical Pharmacology) is titled "Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues"; only its title and citation were available.5 In rats, Trovero and colleagues (Key-Obs S.A., Orléans, France; Neuroscience Letters, 2000) reported that chronic treatment gave "a significant decrease of the kainate binding sites, as measured by quantitative autoradiography".6 In the same chronically treated rats "an increase of D1 dopaminergic (DA) binding sites was measured both in the prefrontal and the cingular cortex, while no modification of the D2 binding sites was detected".6 After an acute injection the same group reported "a decrease of the DA levels in the prefrontal cortex and 3,4-dihydroxyphenylacetic acid levels in both the cingular and the prefrontal cortex".6 The same paper reports that chronic treatment induced "no change in density of N-methyl-D-aspartate (NMDA) and (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in the cingular cortex", and that acute administration produced "a decrease of kainate binding sites but no change of the density of D1 and D2 DA receptors".6 The app's notes mention dopaminergic tone; the rat findings above mix a rise in D1 binding after chronic dosing with lower dopamine-related levels after an acute dose. These are rodent measurements, and no equivalent measurement of brain dopamine or acetylcholine in people taking sulbutiamine was identified in the records searched.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5 h
Bioavailability
90%
Typical dose
200–600 mg/day
Route
Oral
Time to peak
~2 h

The second column of the table holds the app's own figures, shown beside what the French product information reports.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~5 h"La demi-vie est de 5 heures environ" (about 5 hours) in the Arcalion product information1
Time to peak~2 hPeak blood concentration "entre 1 à 2 heures après administration" (1 to 2 hours after administration), so the app's 2 hours is the upper end of that range1
Bioavailability90%No bioavailability figure appears in the Arcalion product information1
RouteOralCoated tablets that are swallowed whole ("Les comprimés sont à avaler tels quels")1
EliminationNot listed"L'élimination est urinaire" (urinary)1

The same text describes sulbutiamine as "rapidement absorbée" (rapidly absorbed).1 The product information does not say whether the 5-hour figure describes sulbutiamine itself or thiamine and metabolites derived from it.1 A human half-life for sulbutiamine did not appear in the 2020 review text or in the PubMed records listed, and the app gives no absorption rate constant or volume of distribution.

4

Human studies

The French product information states that the medicine "a fait l'objet en clinique d'essais contrôlés contre placebo ou produits de référence", without naming the trials.1 The table lists the human studies read in full or as PubMed records; the first two rows are controlled, the third has no comparison group described in its PubMed record, and the fourth is a three-arm trial in children.

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Tiev and colleagues, Hôpital Saint-Antoine, Paris, Revue de médecine interne 19997Randomised, double-blind, parallel-group, placebo-controlled; no funding statement in the PubMed record326 general-practice patients with chronic postinfectious fatigue; 315 completedSulbutiamine 400 mg daily (n = 106), 600 mg daily (n = 111) or placebo (n = 109); 28 daysFatigue scales (mainly MFI) showed overall no significant difference between groups; on day 7 women on 600 mg had less fatigue (P below 0.01), with no persistent effect at day 28
Kiew and colleagues, Universiti Sains Malaysia, Malaysian Journal of Medical Sciences 20028Open randomised controlled trial against no treatment (no placebo); Arcalion made by Servier, no funding statement in the text30 adults with type 2 diabetes and symptomatic distal polyneuropathy (15 per group)Sulbutiamine 400 mg daily or no treatment; 6 weeksNerve conduction velocity and compound muscle action potential improved against control (p below 0.001 for median and peroneal nerves); no significant between-group change in symptom or sign scores; blood glucose and HbA1 unchanged
Sevim and colleagues, Mersin University, Multiple Sclerosis and Related Disorders 20174Single group; patients "were advised to receive" the dose; no comparison group described in the PubMed record; no funding statement there26 patients with multiple sclerosis (18 female, 8 male), aged 18 to 57, with fatigue as a predominant symptomSulbutiamine 400 mg orally once daily; 2 monthsMean Fatigue Impact Scale 77 (SD 30.5) at baseline and 60.5 (SD 29.7) at day 60; 13 of 23 on disease-modifying treatment improved against 0 of 5 not on it; no serious adverse events
Ahmed Mahmoud and colleagues, Sohag University, Egypt, Journal of Pediatric Urology 20269Randomised, three groups; "No potential conflict of interest was reported"; no funding statement in the PubMed record; registry entry lists participant-only masking10450 children aged 6 to 18 with primary monosymptomatic nocturnal enuresisImipramine 25 mg/day, sulbutiamine 100 mg/day, or both; followed 6 monthsComplete response 60% (both), 52.7% (sulbutiamine), 37.3% (imipramine), p = 0.003; relapse 24.8%, 28.7% and 43.6%, p = 0.01; adverse effects 4.7% to 6% with sulbutiamine against 12% to 14% with imipramine, p = 0.017

Deeper analysis: Tiev 1999 trial in postinfectious fatigue

Tiev, Cabane and Imbert (Hôpital Saint-Antoine, Paris) randomised 326 general-practice patients to sulbutiamine 400 mg daily, 600 mg daily or placebo for 28 days in a double-blind, parallel-group design, and 315 completed.7 Fatigue was measured by "multiple means including mainly MFI, a validated multidimensional fatigue scale", and the groups showed "overall no significant difference".7 The one difference reported was in women on 600 mg on day 7, where "the figures were quite diverse and no persistent effect was noted at the 28th day".7 The authors conclude that "Whether the effect observed after 1 week in women represents a true finding needs additional research".7 The PubMed record for the paper gives no funding statement, no author ties to a manufacturer and no stated limitations, and the full text was not available.7 The 2020 review, describing "a sample of 300 patients" from the trial (the PubMed record of the trial gives 326 included), reports that "only 15 patients using sulbutiamine presented side effects" and writes that "these side effects may not be related to sulbutiamine as in the placebo group 12 patients presented similar effects".2,7

Deeper analysis: Kiew 2002 trial in diabetic polyneuropathy

Kiew and colleagues (Universiti Sains Malaysia) recruited 30 patients with type 2 diabetes between 1996 and 1998 and assigned 15 to sulbutiamine and 15 to no treatment.8 Outcomes at baseline and 6 weeks were glucose and HbA1, symptom and sign scores, nerve conduction velocity and compound muscle action potential.8 The groups differed at baseline in peroneal compound muscle action potential (p = 0.045).8 Sign scores improved in 47% of the sulbutiamine group against 20% of controls, with 53% of the sulbutiamine group showing no change or deterioration.8 The authors report "no significant improvement between the two groups for symptom and sign scores", with a significant change in sign scores only against baseline in the sulbutiamine group (p = 0.014).8 The authors state that the symptom score "did not improve, possibly due to the short duration of the study".8 Their listed limitations include that "it was an open controlled trial where examiner bias could not be ruled not and the placebo effect could play a role in the clinical improvement observed", that the patients "were not from a homogenous group", and that "thiamine level was not measured in this study due to financial constraint".8 The article names the product as Arcalion "manufactured by Les Laboratoires Servier" and the text read gives no funding statement and no adverse event reporting.8

Deeper analysis: Sevim 2017 study in multiple sclerosis fatigue

Sevim, Kaleağası and Taşdelen (Mersin University) included patients with a Fatigue Impact Scale total above 20, a Beck Depression Inventory score below 17 and no relapse in the previous 3 months, and 26 were selected.4 The outcome was the change in the Fatigue Impact Scale after 400 mg orally once daily for two months.4 The authors report a significant reduction in the total score and in "all three subscales assessing physical, cognitive, and psychosocial functioning".4 Improvement was seen in 13 of 23 patients on disease-modifying treatment and in none of 5 not on such treatment.4 The authors conclude that the drug "is well-tolerated by all" and that the observation "may encourage further evaluations", and they state no limitations in the PubMed record.4 The 2020 review calls it a "retrospective observational study" and refers to its "methodological limitations".2 The PubMed record gives no funding statement or conflict statement, and the study has no comparison group in that record, so the change cannot be separated from natural variation in fatigue.4

Deeper analysis: Ahmed Mahmoud 2026 trial in nocturnal enuresis

Ahmed Mahmoud and colleagues (Sohag University, Egypt; Journal of Pediatric Urology, 2026) randomised 450 children aged 6 to 18 into imipramine 25 mg/day, sulbutiamine 100 mg/day, or both, and followed them for six months.9 The primary outcomes were "treatment response (complete, partial, or none) and relapse rate"; secondary outcomes included time to dryness and adverse events.9 Mean time to successful therapy was 3.2 ± 1.9 months with sulbutiamine, 3.3 ± 1.8 with the combination and 3.8 ± 1.9 with imipramine alone (p = 0.017).9 Complete response at six months was 60% with the combination, 52.7% with sulbutiamine and 37.3% with imipramine (p = 0.003), so complete response was not reached in 40%, 47.3% and 62.7% respectively.9 The registry entry (NCT06497647) lists Sohag University as the organisation, with status UNKNOWN and last known status RECRUITING.10 It states a start date of 2024-03-01, a first submission date of 2024-07-01, and follow-up "every 1 month till 3 months" at 100 mg daily "for 1 month", whereas the paper reports six months of follow-up.10,9 The registry's primary outcome is the reduction in the number of wet nights, whereas the paper names treatment response and relapse rate.10,9 The authors report no conflict of interest, and the PubMed record gives no funding statement and no stated limitations.9 The French product information states that Arcalion is for adults and that safety and efficacy in children and adolescents have not been established.1

Other human studies described in the 2020 review

The review describes a multicentre placebo-controlled trial by Loo and colleagues in which "the administration of 600 mg/day of sulbutiamine for 8 weeks significantly decreased social inhibition associated with the depressive event", while "no antidepressant effect of sulbutiamine was reported in patients with major depressive episodes".2 The original paper for that trial was not among the sources read, so its numbers, funding and limitations are not reported here.2

5

Doses reported in studies and on labels

The table gives each dose as the source states it, with its comparator and length.

Table 5.1Doses reported in studies and on labels6 rows
Source and peopleDose and routeLengthComparatorReference
Arcalion 200 mg product information, adults only2 to 3 tablets a day, each tablet 200 mg, oral, split between the morning and midday mealsTreatment limited to 4 weeksNot applicable1
Tiev 1999, 326 patients with postinfectious fatigue400 mg or 600 mg daily, oral28 daysPlacebo (n = 109)7
Kiew 2002, 30 patients with diabetic polyneuropathy400 mg daily, oral6 weeksNo treatment (n = 15)8
Sevim 2017, 26 patients with multiple sclerosis400 mg once daily, oral2 monthsNone described4
Ahmed Mahmoud 2026, 450 children aged 6 to 18100 mg/day, oral (alone or with imipramine 25 mg/day)Followed 6 monthsImipramine 25 mg/day9
Loo and colleagues trial as described in the 2020 review, depression600 mg/day8 weeksPlacebo2

The app's typical range is 200 to 600 mg/day, and the label's 2 to 3 tablets of 200 mg is 400 to 600 mg a day, so the app's lower end of 200 mg/day corresponds to one tablet and is below the label's range.1 No trial dose of 200 mg/day appears in the sources read.

The Arcalion product information lists agitation, headache, tremor, nausea, vomiting, rash and malaise as "Peu fréquent" (uncommon), and stomach pain and diarrhoea with frequency "Indéterminée" (cannot be estimated from the data).1 It describes overdose as agitation with euphoria and tremor of the extremities, and says these symptoms are transient.1 The product information states that no specific interaction study was done, that diuretics increase urinary excretion of thiamine, and that Arcalion "ne doit pas être utilisé pendant lallaitement" (is not to be used during breastfeeding).1 The 2020 review cites Shah as reporting side effects in 0.6% of patients using sulbutiamine, and "In a total of 1,772 patients, 5 presented nausea, 1 headache, 1 insomnia, 1 diarrhea, 1 tremor, and 1 drowsiness".2 It also cites Ollat and colleagues, where "3 patients out of 40 (8%) using sulbutiamine in a standalone therapy had headache/insomnia as a side effect".2 In rhesus monkeys given 300 mg/kg/day, an animal study reports hypersalivation in 2 of 6 animals.2 In the 2026 enuresis trial, adverse effects were reported in 4.7% to 6% of children on sulbutiamine and 12% to 14% on imipramine.9 Douzenis and colleagues (Athens University Medical School, World Journal of Biological Psychiatry, 2006) present one patient with bipolar disorder and "addiction to sulbutiamine" whose "need to consume ever increasing quantities of sulbutiamine" compromised psychiatric care.11 A single case report gives no rate of such use.11

The app lists no markers to monitor for sulbutiamine. In the Kiew trial, blood glucose and HbA1 were measured, with glycaemic control "stable throughout the study" in both groups, and thiamine level was not measured.8 Sobolevsky and Rodchenkov (Moscow Antidoping Centre, Drug Testing and Analysis, 2010) reported that "one of the sulbutiamine metabolites has very close retention time and the same characteristic ion (m/z 194) as the main boldenone metabolite".12 They reprocessed screening data and reported that of ca. 16 000 urine samples analysed in the Russian laboratory during 2009 "about 100 samples contained sulbutiamine".12 Most were collected in competition with an estimated concentration "greater than 500 ng/ml", and the authors write that this "may indicate that sulbutiamine was intentionally administered for its ergogenic and mild stimulating properties".12 The 2020 review gives a different count for the same group, "2% of 5,151 antidoping urine samples", and notes the paper "gives no information as to the route of administration and the dose used".2

The French product information is for Arcalion 200 mg, held by Les Laboratoires Servier, with ATC code A11DA02 in the class "Vitamine B1, non associée".1 Its closing line reads "Médicament non soumis à prescription médicale" (medicine not subject to medical prescription), in text dated "ANSM - Mis à jour le : 16/06/2021", which differs from the app's note of prescription status in France.1 The text read is a copy on a third-party site, and a current ANSM listing was not read.1 The US Food and Drug Administration, in a warning letter dated "April 15, 2025" to one company about the product "Sulbutiamine Plus Brain Support", wrote that "sulbutiamine is not a dietary ingredient".13 A footnote states that the letter "does not address whether sulbutiamine can be lawfully marketed in dietary supplements as a non-dietary ingredient".13 No DailyMed label for sulbutiamine was identified, and none of the sources read addresses the app's note that it is unscheduled in the US. The text of the WADA 2026 Prohibited List read does not name sulbutiamine.14 Its S0 class covers any substance "not addressed by any of the subsequent" sections and with no current approval by any governmental regulatory health authority for human therapeutic use.14 The 2020 review says there is some evidence of anti-fatigue, nootropic and antioxidant effects, "which led to its use as a sport supplement (although some authors argue it is actually a masking doping strategy)".2

9

Storage and handling

The product information gives a shelf life of 3 years for blister packs and 2 years for bottles.1 It states that blister-pack tablets "doivent être conservés à une température ne dépassant pas 25°C (zones climatiques I et II)" and bottled tablets not above 30°C (zones III and IV).1

The sources read give no bioavailability figure for sulbutiamine, so the app's 90% stands without a figure from a source.1 Whether intact sulbutiamine reaches the human brain is not shown in the sources read; the 2020 review says it "has never been identified in animal brain in its natural chemical structure".2 The only placebo-controlled fatigue trial read (Tiev 1999) reported no overall difference, the MS fatigue study had no comparison group in its PubMed record, and the diabetic neuropathy trial was open-label.7,4,8 The label limits treatment to 4 weeks, while Kiew used 6 weeks, the MS study 2 months, the Loo trial as described in the 2020 review 8 weeks, and the enuresis trial followed children for 6 months, so treatment beyond 4 weeks is described in the sources only in those studies.1,8,4,2,9 The app's notes describe pre-workout focus, and the only sports-related data read are urine detection counts, with no study of performance.12 The frequency of misuse or dependence is not reported in the sources read, which include one case report.11

What is the half-life of sulbutiamine?

The Arcalion product information gives a half-life of about 5 hours, and the app lists 5 hours.1 The text does not say whether this refers to sulbutiamine itself or to metabolites such as thiamine.1

How long does sulbutiamine take to reach its peak level?

The Arcalion product information gives peak blood concentration at 1 to 2 hours after administration, and the app lists about 2 hours.1

Is sulbutiamine banned by WADA?

The WADA 2026 Prohibited List text read does not name sulbutiamine.14 Its S0 class covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and the French product information shows a marketed medicine.14,1

Is sulbutiamine a prescription drug in France?

The French product information for Arcalion ends with "Médicament non soumis à prescription médicale" (not subject to medical prescription), which differs from the app's note.1 The text read is dated 16 June 2021 and is a copy on a third-party site.1

Is sulbutiamine FDA approved?

No DailyMed label for sulbutiamine was identified. In a 2025 warning letter to one company, the FDA wrote that "sulbutiamine is not a dietary ingredient".13 A footnote in the letter states that it "does not address whether sulbutiamine can be lawfully marketed in dietary supplements as a non-dietary ingredient".13

Does sulbutiamine cross the blood-brain barrier?

Sevim and colleagues describe it as crossing the blood-brain barrier "more readily than thiamine".4 The 2020 review adds that the molecule "has never been identified in animal brain in its natural chemical structure after oral or even parenteral administration".2

Does sulbutiamine work for fatigue?

In the placebo-controlled trial of 326 patients with postinfectious fatigue, Tiev and colleagues reported "overall no significant difference between the groups" at 400 mg or 600 mg daily for 28 days.7 In a 26-patient multiple sclerosis study with no comparison group described, the Fatigue Impact Scale mean fell from 77 to 60.5.4

What side effects does the Arcalion label list?

The label lists agitation, headache, tremor, nausea, vomiting, rash and malaise as uncommon ("Peu fréquent").1 Stomach pain and diarrhoea are listed with frequency "Indéterminée".1

Does sulbutiamine show up in drug tests?

Sobolevsky and Rodchenkov reported that about 100 of ca. 16 000 urine samples analysed in a Russian laboratory in 2009 contained sulbutiamine.12 They also reported that one metabolite shares its retention time and characteristic ion with the main boldenone metabolite.12

13

References

  1. Les Laboratoires Servier. Arcalion 200 mg, comprimé enrobé. Résumé des caractéristiques du produit (ANSM text updated 16 June 2021, as reproduced on pharma-gdd.com). French product information
  2. Starling-Soares B, Carrera-Bastos P, Bettendorff L. Role of the Synthetic B1 Vitamin Sulbutiamine on Health. J Nutr Metab 2020. PMC7210561
  3. Van Reeth O. Pharmacologic and therapeutic features of sulbutiamine. Drugs Today (Barc) 1999. PMID 12973384
  4. Sevim S, et al. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. Mult Scler Relat Disord 2017. PMID 28755683
  5. Bettendorff L, et al. Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues. Biochem Pharmacol 1990. PMID 2268373
  6. Trovero F, et al. Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. Neurosci Lett 2000. PMID 10996447
  7. Tiev KP, et al. Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo. Rev Med Interne 1999. PMID 10573727
  8. Kiew KK, et al. Effects of Sulbutiamine on Diabetic Polyneuropathy: An Open Randomised Controlled Study in Type 2 Diabetics. Malays J Med Sci 2002. PMC3436103
  9. Ahmed Mahmoud T, et al. Comparative evaluation of sulbutiamine and imipramine in the treatment of primary nocturnal enuresis: A randomized controlled clinical study. J Pediatr Urol 2026. PMID 42107294
  10. Sohag University. New Treatment for Nocturnal Enuresis in Children. ClinicalTrials.gov NCT06497647. NCT06497647
  11. Douzenis A, et al. Sulbutiamine, an 'innocent' over the counter drug, interferes with therapeutic outcome of bipolar disorder. World J Biol Psychiatry 2006. PMID 16861144
  12. Sobolevsky T, Rodchenkov G. Sulbutiamine in sports. Drug Test Anal 2010. PMID 21204296
  13. US Food and Drug Administration. Warning letter to Gluten Free Remedies LLC, MARCS-CMS 687832, 15 April 2025. FDA warning letter
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list